The entity in question is a biopharmaceutical company based in India, primarily involved in discovering, developing, and commercializing novel pharmaceutical products and drug candidates. Its activities encompass contract research and manufacturing services (CRAMS), as well as the development of its own pipeline of New Chemical Entities (NCEs) targeting Central Nervous System (CNS) disorders.
Its significance stems from its contributions to pharmaceutical innovation and its role in providing cost-effective research and manufacturing solutions to global pharmaceutical companies. Established several decades ago, the organization has evolved from a contract research provider to a company with a strong focus on intellectual property creation and drug development, thereby enhancing the pharmaceutical sector by offering innovative solutions.
